Provider review
Superior Remedies Review: A 68-Week Result Presented as Month Six
Superior Remedies does the thing this site keeps asking for: it names the trials behind its numbers. That is also what makes its two errors visible. Its semaglutide page places "~15% average body weight reduction" at MONTH 6, while STEP 1 — the trial it cites — measured −15.6% at week 68, about fifteen and a half months. And the second trial family it cites, SUSTAIN, is the type 2 diabetes program rather than the obesity one, with glycemic endpoints. The magnitudes are close to right; the timeline is compressed by a factor of about 2.6, and half the citation points at the wrong question.
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens superiorremedies.com. A link is not a recommendation to take anything.
Provenance
What Superior Remedies actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Semaglutide — GLP-1 Weight Loss program — $149 per cycle, and the cycle is 30 days rather than a calendar month by its own terms — 12.17 charges a year. It is the only price published on the site and it is labeled a limited-time offer; this program page carries no figure at all. Doseworth prices this company properly.
- Tirzepatide — Advanced Weight Loss program — Covered by the same single site-wide $149 figure; this program page publishes no price of its own.
- GLP-1 Microdose — Longevity & Composition — No price is published on this program page; the site's single $149 figure is the only one anywhere.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
2
Molecules with human evidence
For the use they are sold for, out of 3 products reviewed here. The evidence belongs to the molecule, not to Superior Remedies.
3
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Superior Remedies’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Semaglutide — GLP-1 Weight Loss programSemaglutide · Compounded (503A)Claim reaches past the trials
“CLINICAL AVERAGE ~15% body weight. […] 03 MONTH 6 — ~15% Average body weight reduction reported in published trials. 04 YEAR 1+ Maintained — Most members sustain results with continued physician-directed treatment. […] Outcomes referenced from STEP 1 and SUSTAIN clinical trials.”
Phase 3 trials
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Registry-verified 2026-08-11: primary outcome "Change in Body Weight (%)", timeframe "Baseline (week 0) to week 68", reported as −15.6% on semaglutide 2.4 mg against −2.8% on placebo. Week 68 is about 15.6 months — the trial Superior Remedies cites for a month-six figure.
- NCT02054897 SUSTAIN 1 — Phase 3, completed, n=388. Included to show what the second cited trial family actually studied: its registered condition is "Diabetes Mellitus, Type 2", as it is for every other SUSTAIN trial checked on 2026-08-11. The SUSTAIN program measured glycemic control in people with type 2 diabetes; weight change was a secondary matter and smaller than in STEP.
The magnitude is close and the timeline is not. STEP 1 produced −15.6%, and Superior Remedies says "~15%" — fair. But it places that figure at MONTH 6, and STEP 1 measured it at WEEK 68, which is about fifteen and a half months. A reader planning around this page expects in half a year what the trial took two and a half times as long to deliver. ⚠ The citation is also half wrong: SUSTAIN is the type 2 diabetes program, with glycemic endpoints and a different population, so it cannot support a body-weight claim. ⚠ And as everywhere in this category, STEP 1 tested Novo Nordisk's approved injectable; what is dispensed here is a compounded preparation with no registered trial of its own. ★ None of that erases the credit for naming the trials at all — the error is visible only because the company showed its work.1
Tirzepatide — Advanced Weight Loss programTirzepatide · Compounded (503A)Claim matches the trials
“A dual-agonist GLP-1 / GIP program designed for patients seeking advanced metabolic results under provider direction with flat-rate pricing. CLINICAL AVERAGE ~20% body weight.”
Phase 3 trials
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Registry-verified 2026-08-11: Completed, phase 3, 2,539 participants over 72 weeks, testing the approved injectable tirzepatide at a titrated therapeutic dose. Its top-dose result is close to the ~20% Superior Remedies quotes.
"~20% body weight" is a fair reading of SURMOUNT-1's top-dose result, and the mechanism description — dual GLP-1/GIP agonist — is correct. It also carries the qualifier most of this category drops: "Individual results vary. Ranges reflect clinical data for provider-supervised GLP-1 programs." ⚠ Two caveats keep it from being unqualified. No period is attached to the 20%, and SURMOUNT-1 ran 72 weeks — the same compression that makes the semaglutide claim overstate is latent here, it is simply not spelled out. And the trial tested the approved product rather than the compounded one sold.2
GLP-1 Microdose — Longevity & CompositionSemaglutide · Compounded (503A)No trial supports this claim
“A lower-dose GLP-1 protocol designed for metabolic health, body composition, and appetite regulation. […] ✕ CLINICAL EXCLUSION: Patients with significant weight to lose who would be better served by a standard GLP-1 protocol.”
No human trial
The molecule has a large phase 3 program; this USE does not. ClinicalTrials.gov was searched on 2026-08-11 for completed interventional studies pairing semaglutide or tirzepatide with longevity, healthspan, aging or body-composition endpoints. ★ ONE COMPLETED TRIAL COMES CLOSE AND IS WORTH NAMING RATHER THAN BURYING: NCT05786521, "Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults" — completed, phase 4, and it registers Aging itself as a condition, with lean body mass change from baseline to twenty weeks as its primary outcome. ⛔ IT IS NOT A MICRODOSE TRIAL, WHICH IS THE WHOLE POINT. Its published regimen titrates 0.25 mg weekly to 0.5 mg to 1.0 mg and holds there for twelve weeks — 1.0 mg is a standard maintenance dose, not a deliberately reduced one — and it enrolled twenty people, which is a pilot rather than a basis for a product claim. So the nearest registered evidence for "lower dose, different benefit" tested a normal dose in twenty patients. The remaining searches returned no completed trial of a sub-therapeutic regimen against these endpoints at all.
Selling a reduced dose for "metabolic health" and "body composition" asserts that less of the drug produces a different category of benefit, and no registered trial has tested that regimen for those endpoints. The appetite-regulation half is on firmer ground — appetite is what GLP-1 receptor agonists demonstrably act on — but the longevity-and-composition framing in the program's own name is not. ★ One thing here deserves real credit and is rare enough to name: the page carries a CLINICAL EXCLUSION for "patients with significant weight to lose who would be better served by a standard GLP-1 protocol". Most microdose marketing in this category is aimed squarely at that customer. Turning them away, in writing, is the opposite of what this site usually finds.1
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named. Superior Remedies describes itself as "a concierge telehealth platform that facilitates access to independent, U.S. board-certified clinical providers and state-licensed compounding pharmacies", and adds that "the platform does not practice medicine, write prescriptions, or dispense pharmaceuticals" — a clearer statement of what it is than most of this roster offers, attached to no pharmacy name, address or license number. Its footer states fulfillment is "Compounded in the USA". No compounding category appears: neither 503A nor 503B is mentioned.
Read on August 2026 from https://superiorremedies.com/
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, lot number, potency result or testing laboratory is published. The nearest statements are "Compounded in the USA" and the disclosure that compounded medications "are not FDA-approved and their safety, efficacy, and quality have not been independently verified by the FDA" — which is a candid admission rather than a quality claim, and is more than several companies in this roster manage.
Read on August 2026 from https://superiorremedies.com/
Licensing
Licensed to dispense, and where
Coverage
Superior Remedies claims "TELEHEALTH IN ALL 50 STATES" in its badge strip and repeats "Telehealth nationwide" on its program pages. No excluded set is published and no state list is given to test the claim against, so it is recorded as the company's own and no exclusion is asserted.
Read the full licensing claim
"Independent, U.S. board-certified clinical providers", with the platform stating it does not itself practice medicine or write prescriptions. No individual clinician is named.
Read on August 2026 from https://superiorremedies.com/
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- It names the trials behind its numbers — "Outcomes referenced from STEP 1 and SUSTAIN clinical trials" — which almost nothing else in this roster does.
- Its tirzepatide figure, ~20%, is a fair reading of SURMOUNT-1's top-dose result, and its mechanism description is correct.
- Its microdose page excludes the very customers most microdose marketing targets: "patients with significant weight to lose who would be better served by a standard GLP-1 protocol".
Show 3 more
- It prints the disclosure two companies in this roster hold open FDA warning letters for omitting — compounded medications "are not FDA-approved and their safety, efficacy, and quality have not been independently verified by the FDA".
- It states plainly that it is a platform and does not practice medicine, write prescriptions or dispense pharmaceuticals.
- "$0 if you're not approved" is backed by a terms clause rather than left as a slogan.
- It places semaglutide's ~15% at MONTH 6. STEP 1 measured −15.6% at week 68 — about fifteen and a half months — so the timeline is compressed by a factor of roughly 2.6.
- Half its citation points at the wrong trial family: SUSTAIN is the type 2 diabetes program with glycemic endpoints, not the obesity program.
- Its microdose program is named for "Longevity & Composition" and no registered trial tests a sub-therapeutic GLP-1 regimen against either.
Show 4 more
- No period is attached to the tirzepatide ~20% either, so the same compression is available to a reader without being stated.
- Both trials cited tested approved products; what is dispensed is compounded and has no registered trial of its own.
- No pharmacy is named and no compounding category is stated.
- No certificate of analysis or testing result is published for any product.
Verdict
The bottom line
Superior Remedies is caught by its own honesty, which is an unusual way to be caught. It names STEP 1 and SUSTAIN as the source of its numbers, and naming them is what makes it checkable that one of the two is the diabetes program rather than the obesity one, and that the ~15% it places at month six was measured at week 68. The magnitudes are broadly right — ~15% for semaglutide and ~20% for tirzepatide are close to what the trials produced — so this is not a company inventing outcomes. It is a company describing real outcomes on a timeline the trials do not support, and borrowing half its authority from studies that were measuring blood sugar. Set against that: a microdose page that turns away the customers it could most easily sell to, a plain not-FDA-approved disclosure, and a refund term that means what it says. Read the numbers, ignore the calendar.
Opens superiorremedies.com. A link is not a recommendation to take anything.
It names its trials, and that is why this review can be specific
"Outcomes referenced from STEP 1 and SUSTAIN clinical trials."
Almost nothing else reviewed on this site tells you where its numbers came from. Superior Remedies does — and everything below follows from that, because a company that cites nothing cannot be shown to have cited the wrong thing.
Full analysis — 3 more sectionsThe month-six problem · Half the citation is the wrong program · The microdose program, and the line it draws
The month-six problem
From its semaglutide program page:
"03 MONTH 6 ~15% Average body weight reduction reported in published trials."
STEP 1 (NCT03548935), registry-verified on 11 August 2026:
- Primary outcome — Change in Body Weight (%)
- Timeframe — Baseline (week 0) to week 68
- Result — −15.6% on semaglutide, −2.8% on placebo
Week 68 is about fifteen and a half months. The page presents that result as a month-six milestone, which compresses the trial's timeline by a factor of roughly 2.6.
The magnitude is honest. The calendar is not, and the calendar is what a patient plans around.
Half the citation is the wrong program
STEP is the obesity program. SUSTAIN is the type 2 diabetes program — checked against the registry, where SUSTAIN 1 (NCT02054897), SUSTAIN 4 (NCT02128932) and the rest all carry Diabetes Mellitus, Type 2 as their registered condition and glycemic endpoints as their primary outcomes.
Weight change in the SUSTAIN trials was a secondary observation in a different population being asked a different question. It cannot support a body-weight claim, and citing it alongside STEP lends the number authority it did not earn.
The microdose program, and the line it draws
The GLP-1 Microdose page sells "a lower-dose GLP-1 protocol designed for metabolic health, body composition, and appetite regulation". No registered trial tests a deliberately sub-therapeutic GLP-1 regimen against longevity, healthspan or body-composition endpoints — the STEP program titrated up to therapeutic doses and measured weight and cardiometabolic outcomes.
But the same page carries this:
"✕ CLINICAL EXCLUSION: Patients with significant weight to lose who would be better served by a standard GLP-1 protocol."
That is a company declining, in writing, to sell its longevity product to the customer with the biggest and most motivated problem. In this category that is genuinely rare, and it is worth putting next to the criticism above.
Questions
Frequently asked questions
Will I lose 15% of my body weight in six months?
Not on the evidence the page cites. Superior Remedies places "~15%" at month six, and STEP 1 — the trial it names — measured −15.6% at week 68, which is about fifteen and a half months. The magnitude is right and the timeline is compressed by roughly a factor of 2.6. Loss on these drugs is front-loaded, so month six is real progress; it is not, on this trial, the 15% figure.
Are STEP and SUSTAIN the same thing?
No, and the difference matters for a weight-loss claim. STEP is semaglutide's obesity program, and STEP 1 is where the ~15% comes from. SUSTAIN is its type 2 diabetes program — every SUSTAIN trial checked in the registry lists Diabetes Mellitus, Type 2 as its condition, with glycemic endpoints in a different population. Citing both as the source of a body-weight number means half the citation is answering a different question.
Is there evidence for GLP-1 microdosing for longevity or body composition?
No. No completed registered trial tests a sub-therapeutic GLP-1 regimen against longevity, healthspan or body-composition endpoints. The STEP program titrated up to full therapeutic doses and measured weight and cardiometabolic outcomes; it did not test a reduced dose and did not measure aging. Appetite regulation is on firmer ground — that is the mechanism these drugs demonstrably act through — but the "Longevity & Composition" framing in the program's own name is not supported. Credit where it is due: the same page refuses the customer most microdose marketing chases, excluding "patients with significant weight to lose".
Is Superior Remedies related to telos rx?
Not on anything either company publishes. telos rx's legal entity is Superior Health Solutions LLC and this one's is Superior Remedies LLC, each read off its own terms of service. They share a first word and nothing else that either site discloses — no common address, no shared operator statement, no cross-reference. This network has previously mistaken a shared word for evidence, and it is not repeated here.
Glossary
Key terms
Show definitions
- STEP program
- Semaglutide's phase 3 trial program in overweight and obesity, measuring percentage change in body weight. STEP 1 enrolled 1,961 adults and reported −15.6% at week 68.
- SUSTAIN program
- Semaglutide's phase 3 trial program in type 2 diabetes, measuring glycemic control. A different population and different endpoints from STEP; weight change appears as a secondary observation.
- Timeline compression
- Quoting a trial's endpoint result against a shorter period than the trial ran. The number is real and the schedule is not, which matters because a patient decides whether treatment is working against the schedule they were given.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Superior Remedies's own pages on the date stamped against it, and the URL it came from is published beside it.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.